PepGen's Promising Clinical Milestones and Strategic Advancements Earn a Buy Rating

Analyst Ananda Ghosh of H.C. Wainwright maintains a Buy rating on PepGen Inc. with a price target of $8.00, citing the completion of dosing in the FREEDOM-DM1 trial's 15 mg/kg cohort and robust splicing correction at lower doses. The safety profile of PepGen's EDO platform and potential for acquisition interest in the growing DM1 market also contribute to the positive outlook. Ghosh has a 3-star analyst rating with an average return of 8.8% and a 55.56% success rate.

PepGen Inc. (PEPG), a clinical-stage biotechnology company, recently reported its second-quarter 2025 financial results and corporate highlights. The company, which focuses on developing next-generation oligonucleotide therapies for severe neuromuscular and neurological disorders, provided updates on its myotonic dystrophy type 1 (DM1) program and financial performance.

Clinical Progress

The company completed patient dosing in the 15 mg/kg cohort of the FREEDOM trial for PGN-EDODM1, with topline data expected in early Q4 2025. Based on positive splicing correction results and safety data, PepGen will conclude the FREEDOM trial at the 15 mg/kg dose level and transition to FREEDOM2, its Phase 2 multiple ascending dose study. The company expects to report results from the 5 mg/kg cohort of FREEDOM2 in Q1 2026 [1].

Financial Performance

Financial highlights include $74.7 million in cash and equivalents as of June 30, 2025, with runway into Q2 2026. The company reported a net loss of $23.1 million, or $(0.70) per share, for Q2 2025, compared to $28.3 million in Q2 2024 [1].

Analyst Perspective

Analyst Ananda Ghosh of H.C. Wainwright maintains a Buy rating on PepGen Inc. with a price target of $8.00. Ghosh cited the completion of dosing in the FREEDOM-DM1 trial's 15 mg/kg cohort and robust splicing correction at lower doses. The safety profile of PepGen's EDO platform and potential for acquisition interest in the growing DM1 market also contribute to the positive outlook [2].

References

[1] https://www.stocktitan.net/news/PEPG/
[2] https://www.stocktitan.net/news/PEPG/